Literature DB >> 21224858

The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation.

M Mohty, R F Duarte, S Croockewit, K Hübel, G Kvalheim, N Russell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21224858     DOI： 10.1038/leu.2010.224

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  24 in total

Review 1.  Towards in vivo amplification: Overcoming hurdles in the use of hematopoietic stem cells in transplantation and gene therapy.

Authors:  Murtaza S Nagree; Lucía López-Vásquez; Jeffrey A Medin
Journal:  World J Stem Cells       Date:  2015-12-26       Impact factor: 5.326

2.  Use of biosimilar filgrastim compared with lenograstim in autologous haematopoietic stem-cell transplant and in sibling allogeneic transplant.

Authors:  Shab Uddin; Pippa Russell; Maresa Farrell; Barbara Davy; Joe Taylor; Samir G Agrawal
Journal:  Ther Adv Hematol       Date:  2015-04

Review 3.  Adult haematopoietic stem cell niches.

Authors:  Genevieve M Crane; Elise Jeffery; Sean J Morrison
Journal:  Nat Rev Immunol       Date:  2017-06-12       Impact factor: 53.106

4.  The choice of in-hospital or home administration for plerixafor injection to poor mobilizers has no adverse consequence on subsequent hematopoietic stem cell harvest.

Authors:  C Chabannon; F Bijou; J-M Grouin; P Drillat; N Milpied; M Mohty
Journal:  Bone Marrow Transplant       Date:  2017-06-05       Impact factor: 5.483

5.  Addition of plerixafor to G-CSF is useful to achieve efficient collection even in very poor mobilizers: hope for patients with diminished hematopoietic function.

Authors:  M Mohty; P Drillat; J-M Grouin; F Bijou; N Milpied; C Chabannon
Journal:  Bone Marrow Transplant       Date:  2017-05-22       Impact factor: 5.483

Review 6.  Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers.

Authors:  Mohamad Mohty; Jean-Luc Harousseau
Journal:  Haematologica       Date:  2014-03       Impact factor: 9.941

Review 7.  Enhancing the efficacy of mesenchymal stem cell therapy.

Authors:  Michalis Mastri; Huey Lin; Techung Lee
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

Review 8.  Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2011-08-20       Impact factor: 9.546

Review 9.  Acute myelogenous leukemia stem cells: from Bench to Bedside.

Authors:  J Felipe Rico; Duane C Hassane; Monica L Guzman
Journal:  Cancer Lett       Date:  2012-06-17       Impact factor: 8.679

10.  Activation of Toll-like receptor 3 amplifies mesenchymal stem cell trophic factors and enhances therapeutic potency.

Authors:  Michalis Mastri; Zaeem Shah; Terence McLaughlin; Christopher J Greene; Leah Baum; Gen Suzuki; Techung Lee
Journal:  Am J Physiol Cell Physiol       Date:  2012-07-25       Impact factor: 4.249
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.